Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | GRM7 | Q14831 | 4/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18263470 | 0.83 | MAPT (0.45) | MAPTGRM7MTNR1AMTNR1BIDO1 | |
| SCHEMBL12935942 | 0.81 | GRM7 (0.53) | MAPTGRM7MTNR1AMTNR1BIDO1 | |
| SCHEMBL4513633 | 0.81 | TP53 (0.53) | MAPTMTNR1ALMNA | |
| SCHEMBL21810914 | 0.81 | TP53 (0.53) | MAPTMTNR1ALMNA | |
| SCHEMBL31277869 | 0.81 | TP53 (0.53) | MAPTMTNR1ALMNA | |
| SCHEMBL18263411 | 0.80 | MEN1 (0.47) | MAPTGRM7MTNR1AMTNR1BIDO1 | |
| SCHEMBL3441786 | 0.80 | CA1 (0.43) | LMNA | |
| SCHEMBL4607688 | 0.78 | MAPT (0.45) | MAPTNPC1RAB9A | |
| SCHEMBL10817102 | 0.78 | MTNR1A (0.44) | MAPTMTNR1AMTNR1BLMNAKDM4E | |
| SCHEMBL2078174 | 0.77 | MLYCD (0.51) | MAPTNPC1LMNARAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487781-B1 | PROCESS FOR PREPARING 2-AMINOINDAN DERIVATIVES | NOVARTIS AG (CH) | 2008-07-23 | — | — | EP | claimed |
| CN-1268605-C | Process for preparing 2-aminoindan derivatives | NOVARTIS AG (CH) | 2006-08-09 | — | — | CN | claimed |
| US-6933410-B2 | Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine | NOVARTIS AG (CH) | 2005-08-23 | — | — | US | claimed |
| CN-1639111-A | Process for preparing 2-aminoindan derivatives | NOVARTIS AG (CH) | 2005-07-13 | — | — | CN | claimed |
| US-20030187301-A1 | Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine | NOVARTIS AG (CH) | 2003-10-02 | — | — | US | claimed |
| CN-116041230-B | NLRP3 inflammation small inhibitor and preparation method and application thereof | 中国海洋大学 | 2024-03-19 | — | — | CN | disclosed |
| CN-116041230-A | NLRP3 inflammation small inhibitor and preparation method and application thereof | 中国海洋大学 | 2023-05-02 | — | — | CN | disclosed |
| EP-1876179-B1 | Thienopyrimidone compounds | TAKEDA PHARMACEUTICAL (JP) | 2015-03-25 | — | — | EP | disclosed |
| EP-1876179-B1 | Thienopyrimidone compounds | TAKEDA PHARMACEUTICAL (JP) | 2015-03-25 | — | — | EP | disclosed |
| US-7989445-B2 | Thienopyrimidone compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-02 | — | — | US | disclosed |
| US-7989445-B2 | Thienopyrimidone compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-02 | — | — | US | disclosed |
| US-7989445-B2 | Thienopyrimidone compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-02 | — | — | US | disclosed |
| CN-1268605-C | Process for preparing 2-aminoindan derivatives | NOVARTIS AG (CH) | 2006-08-09 | — | — | CN | disclosed |
| US-20050282819-A1 | Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia | GRAHAM JAMES M | 2005-12-22 | — | — | US | disclosed |
| US-6933410-B2 | Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine | NOVARTIS AG (CH) | 2005-08-23 | — | — | US | disclosed |
| CN-1639111-A | Process for preparing 2-aminoindan derivatives | NOVARTIS AG (CH) | 2005-07-13 | — | — | CN | disclosed |
| WO-2005056540-A1 | HETEROCYCLIC SUBSTITUTED INDANE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-23 | — | — | WO | disclosed |
| EP-1487781-A2 | PROCESS FOR PREPARING 2-AMINOINDAN DERIVATIVES | Novartis AG (CH) | 2004-12-22 | — | — | EP | disclosed |
| US-20030187301-A1 | Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine | NOVARTIS AG (CH) | 2003-10-02 | — | — | US | disclosed |
| WO-2003076387-A2 | PROCESS FOR PREPARING 2-AMINOINDAN DERIVATIVES | NOVARTIS AG (CH) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282819-A1 | Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia | CHRM1, CHRM2, CHRM5 | MAPT 1734/4885GRM7 66/4885MTNR1A 79/4885 |
| US-20030187301-A1 | Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine | NAT1, AADAC, IDH3A | MAPT 2277/4885GRM7 2328/4885MTNR1A 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.